Top ▲

tumor associated calcium signal transducer 2

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 2837

Nomenclature: tumor associated calcium signal transducer 2

Family: Tumour-associated antigens

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 323 1p32.1 TACSTD2 tumor associated calcium signal transducer 2
Mouse 1 317 6 C1 Tacstd2 tumor-associated calcium signal transducer 2
Rat 1 317 4q31 Tacstd2 tumor-associated calcium signal transducer 2
Previous and Unofficial Names Click here for help
M1S1 | EGP-1 | TROP2 | TROP-2 | GA733-1 | RS7 antigen [2] | tumor-associated calcium signal transducer 2
Database Links Click here for help
Alphafold
CATH/Gene3D
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
hIMB1636-MMAE Peptide Hs Binding 9.1 pKd 3
pKd 9.1 (Kd 7x10-10 M) [3]
Description: Binding affinity for recombinant antigen
sacituzumab govitecan Peptide Approved drug Primary target of this compound Hs Binding - - 1
[1]
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Corneal dystrophy, gelatinous drop-like; GDLD
Synonyms: Gelatinous drop-like corneal dystrophy [Orphanet: ORPHA98957]
OMIM: 204870
Orphanet: ORPHA98957
Disease:  Honey-droplet corneal dystrophy
Orphanet: ORPHA98958
General Comments
TROP2 is a an antigen that is overexpressed on the surface of tumours of the lung, breast, pancreas and other organs. Elevated TROP2 expression is associated with poor prognosis. The first anti-TROP2 ADC to be approved was Immunomedics' sacituzumab govitecan (Trodelvy®) in April 2020. AstraZeneca, in partnership with Daiichi Sankyo, have anti-TROP2 ADC DS-1062 in advanced clinical development. DS-1062 is a humanised mAb conjugated to the exatecan derivative MAAA1181a (a.k.a. DXd).

References

Show »

1. Govindan SV, Qu Z, Hansen HJ, Goldenberg DM. (2013) RS7 antibodies. Patent number: US8574575. Assignee: Immunomedics, Inc.. Priority date: 01/03/2002. Publication date: 05/11/2013.

2. Stein R, Basu A, Goldenberg DM, Lloyd KO, Mattes MJ. (1994) Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7. Int J Cancer Suppl, 8: 98-102. [PMID:8194903]

3. Sun LP, Bai WQ, Zhou DD, Wu XF, Zhang LW, Cui AL, Xie ZH, Gao RJ, Zhen YS, Li ZR et al.. (2023) hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer. J Med Chem, 66 (21): 14700-14715. [PMID:37883180]

How to cite this page

Tumour-associated antigens: tumor associated calcium signal transducer 2. Last modified on 27/10/2023. Accessed on 22/02/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2837.